Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Abbisko Cayman Limited ( (HK:2256) ).
Abbisko Cayman Limited announced that its subsidiary Abbisko Therapeutics has received clearance from China’s National Medical Products Administration for an Investigational New Drug application to begin clinical trials of ABSK141, an oral, highly potent and selective small-molecule inhibitor targeting KRAS G12D mutations in patients with advanced solid tumors. The open-label Phase I/II study will evaluate the safety, tolerability, efficacy and pharmacokinetics of ABSK141 in cancers such as pancreatic, colorectal and non-small cell lung cancer, positioning Abbisko in the competitive race to develop the first targeted therapy against the notoriously difficult KRAS G12D mutation and potentially strengthening its profile in precision oncology, though the company cautions there is no guarantee the drug will ultimately reach the market.
The most recent analyst rating on (HK:2256) stock is a Hold with a HK$15.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
More about Abbisko Cayman Limited
Abbisko Cayman Limited, through its Shanghai-based subsidiary Abbisko Therapeutics Co., Ltd., is an oncology-focused biopharmaceutical group dedicated to discovering and developing innovative medicines for unmet medical needs in China and globally. Founded in 2016 by veteran drug developers from multinational pharmaceutical companies, Abbisko has built an extensive pipeline centered on precision oncology and immuno-oncology therapies.
Average Trading Volume: 2,680,658
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.17B
Learn more about 2256 stock on TipRanks’ Stock Analysis page.